1. Recurrent gene fusions in prostate cancer.
   Kumar-Sinha C, Tomlins SA, Chinnaiyan AM.
   Nat Rev Cancer. 2008 Jul;8(7):497-511. Epub 2008 Jun 19. Pubmed
2. The role of SPINK1 in ETS rearrangement-negative prostate cancers.
   Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, http://www.compendiabio.com/news/pubs.htmDemichelis F, Helgeson BE, Laxman B, Morris DS, Cao Q, Cao X, Andrén O, Fall K, Johnson L, Wei JT, Shah RB, Al-Ahmadie H, Eastham JA, Eggener SE, Fine SW, Hotakainen K, Stenman UH, Tsodikov A, Gerald WL, Lilja H, Reuter VE, Kantoff PW, Scardino PT, Rubin MA, Bjartell AS, Chinnaiyan AM.
   Cancer Cell. 2008 Jun;13(6):519-28. Pubmed
3. Genomic outlier profile analysis: mixture models, null hypotheses, and nonparametric estimation.
   Ghosh D, Chinnaiyan AM.
   Biostatistics. 2008 Jun 6. Pubmed
   
4. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.
   Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andrén O, Johnson LA, Tang J, Adami HO, Calza S, Chinnaiyan AM, Rhodes D, Tomlins S, Fall K, Mucci LA, Kantoff PW, Stampfer MJ, Andersson SO, Varenhorst E, Johansson JE, Brown M, Golub TR, Rubin MA.
   J Natl Cancer Inst. 2008 Jun 4;100(11):815-25. Epub 2008 May 27. Pubmed
   
5. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.
   Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM.
   Cancer Res. 2008 May 15;68(10):3584-90. Pubmed
   
6. The discovery and application of gene fusions in prostate cancer.
   Morris DS, Tomlins SA, Montie JE, Chinnaiyan AM.
   BJU Int. 2008 Apr 16. Pubmed
7. CXCL5 promotes prostate cancer progression.
   Begley LA, Kasina S, Mehra R, Adsule S, Admon AJ, Lonigro RJ, Chinnaiyan AM, Macoska JA.
   Neoplasia. 2008 Mar;10(3):244-54. Pubmed
   
8. Role of the TMPRSS2-ERG gene fusion in prostate cancer.
   Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, Mehra R, Chinnaiyan AM.
   Neoplasia. 2008 Feb;10(2):177-88. Pubmed
   
9. Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer.
   Tseng-Rogenski SS, Arredouani MS, Neeley YC, Lu B, Chinnaiyan AM, Sanda MG.
   Cancer Immunol Immunother. 2008 Sep;57(9):1357-65. Epub 2008 Feb 12. Pubmed
   
10. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.
    Yu J, Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, Mehra R, Wang X, Ghosh D, Shah RB, Varambally S, Pienta KJ, Chinnaiyan AM.
    Cancer Res. 2007 Nov 15;67(22):10657-63. Pubmed
    
11. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.
    Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, Lonigro RJ, Tsodikov A, Wei JT, Tomlins SA, Chinnaiyan AM.
    Cancer Res. 2008 Feb 1;68(3):645-9. Pubmed
    
12. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.
    Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, Cao X, Singla N, Montie JE, Varambally S, Mehra R, Chinnaiyan AM.
    Cancer Res. 2008 Jan 1;68(1):73-80. Pubmed
    
13. Humoral response profiling reveals pathways to prostate cancer progression.
    Taylor BS, Pal M, Yu J, Laxman B, Kalyana-Sundaram S, Zhao R, Menon A, Wei JT, Nesvizhskii AI, Ghosh D, Omenn GS, Lubman DM, Chinnaiyan AM, Sreekumar A.
    Mol Cell Proteomics. 2008 Mar;7(3):600-11. Epub 2007 Dec 11. Pubmed
    
14. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer.
    Yu J, Cao Q, Mehra R, Laxman B, Yu J, Tomlins SA, Creighton CJ, Dhanasekaran SM, Shen R, Chen G, Morris DS, Marquez VE, Shah RB, Ghosh D, Varambally S, Chinnaiyan AM.
    Cancer Cell. 2007 Nov;12(5):419-31. Pubmed
    
15. A latent variable approach for meta-analysis of gene expression data from multiple microarray experiments.
    Choi H, Shen R, Chinnaiyan AM, Ghosh D.
    BMC Bioinformatics. 2007 Sep 27;8:364. Pubmed
    
16. Integrative analysis of genomic aberrations associated with prostate cancer progression.
    Kim JH, Dhanasekaran SM, Mehra R, Tomlins SA, Gu W, Yu J, Kumar-Sinha C, Cao X, Dash A, Wang L, Ghosh D, Shedden K, Montie JE, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM.
    Cancer Res. 2007 Sep 1;67(17):8229-39. Pubmed
    
17. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases.
    Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ, Shen R, Montie JE, Chinnaiyan AM, Shah RB.
    Cancer Res. 2007 Sep 1;67(17):7991-5. Pubmed
    
18. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth.
    Wang Q, Li W, Liu XS, Carroll JS, Jänne OA, Keeton EK, Chinnaiyan AM, Pienta KJ, Brown M.
    Mol Cell. 2007 Aug 3;27(3):380-92. Pubmed
    
19. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
    Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, Roulston D, Shah RB, Varambally S, Mehra R, Chinnaiyan AM.
    Nature. 2007 Aug 2;448(7153):595-9. Pubmed
    
20. The lethal phenotype of cancer: the molecular basis of death due to malignancy.
    Loberg RD, Bradley DA, Tomlins SA, Chinnaiyan AM, Pienta KJ.
    CA Cancer J Clin. 2007 Jul-Aug;57(4):225-41. Review. Erratum in: CA Cancer J Clin. 2007 Nov-Dec;57(6):380. Pubmed
    
21. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.
    Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA.
    Am J Surg Pathol. 2007 Jun;31(6):882-8. Pubmed
    
22. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
    Mosquera JM, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, Rubin MA.
    J Pathol. 2007 May;212(1):91-101. Pubmed
    
23. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.
    Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM, Shah RB.
    Mod Pathol. 2007 May;20(5):538-44. Epub 2007 Mar 2. Pubmed
    
24. Molecular concepts analysis links tumors, pathways, mechanisms, and drugs.
    Rhodes DR, Kalyana-Sundaram S, Tomlins SA, Mahavisno V, Kasper N, Varambally R, Barrette TR, Ghosh D, Varambally S, Chinnaiyan AM.
    Neoplasia. 2007 May;9(5):443-54. Pubmed
25. Integrating biomedical knowledge to model pathways of prostate cancer progression.
    Morris DS, Tomlins SA, Rhodes DR, Mehra R, Shah RB, Chinnaiyan AM.
    Cell Cycle . 2007 May;6(10):1177-87. Pubmed
26. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles.
    Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varmbally R, Yu J, Briggs BB, Barrette TR, Anstett MJ, Kincaid-Beal C, Kulkarni P, Varambally S, Ghosh D, Chinnaiyan AM.
    Neoplasia. 2007 Feb;9(2):166-80. Pubmed
27. Bioinformatics approaches in the study of cancer.
    Hanauer DA, Rhodes DR, Sinha-Kumar C, Chinnaiyan AM.
    Curr Mol Med. 2007 Feb;7(1):133-41. Review. Pubmed
28. Integrative molecular concept modeling of prostate cancer progression.
    Scott A Tomlins, Rohit Mehra, Daniel R Rhodes, Xuhong Cao, Lei Wang, Saravana M Dhanasekaran, Shanker Kalyana-Sundaram, John T Wei, Mark A Rubin, Kenneth J Pienta, Rajal B Shah & Arul M Chinnaiyan.
    Nature Genetics 2007 Jan.; 39, 41 - 51 Pubmed
29. Bioinformatics approach leads to the discovery of the TMPRSS2: ETS gene fusion in prostate cancer.
    Rubin MA, Chinnaiyan AM.
    Laboratory Inestigation 2006 Nov; 86 (11): 1099-1102. Pubmed
30. Evidence of recurrent gene fusions in common epithelial tumors.
    Kumar-Sinha C, Tomlins SA, Chinnaiyan AM
    Trends in Molecular Medicine 2006 Nov.; 12 (11): 529-536. Pubmed
31. Differential proteomic alterations between localised and metastatic prostate cancer.
    Taylor BS, Varambally S, Chinnaiyan AM.
    British Journal of Cancer 2006 Aug; 95 (4): 425-430. Pubmed
32. Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation.
    Giordano TJ, Au AYM, Kuick R, Thomas DG, Rhodes DR, Wilhelm KG, Vinco M, Misek DE, Sanders D, Zhu ZW, Ciampi R, Hanash S, Chinnaiyan A, Clifton-Bligh RJ, Robinson BG, Nikiforov YE, Koenig RJ.
    Clinical Cancer Research 2006 Apr 1;12(7 Pt 1):1983-93. Pubmed
33. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.
    Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, Cao X, Wei JT, Rubin MA, Shah RB, Chinnaiyan AM.
    Cancer Res. 2006 Apr 1;66(7):3396-400. Pubmed
34. Whole transcriptome amplification for gene expression profiling and development of molecular archives.
    Tomlins SA, Mehra R, Rhodes DR, Shah RB, Rubin MA, Bruening E, Makarov V, Chinnaiyan AM.
    Neoplasia. 2006 Feb;8(2):153-62. Pubmed
35. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer.
    Fu Z, Kitagawa Y, Shen R, Shah R, Mehra R, Rhodes D, Keller PJ, Mizokami A, Dunn R, Chinnaiyan AM, Yao Z, Keller ET.
    Prostate. 2006 Feb 15;66(3):248-56. Pubmed
36. Integrative biology of prostate cancer progression
    Tomlins SA, Rubin MA, Chinnaiyan AM
    Annual Review of Pathology-Mechanisms of Disease 1 (1): 243-271 2006.
37. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis.
    Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D, Chinnaiyan AM, Kleer CG.
    Cancer Res. 2005 Dec 15; 65(24):11259-64. Pubmed
38. The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells.
    Zeidler, M., Varambally, S., Cao, Q., Chinnaiyan, A. M., Ferguson, D. O., Merajver, S. D., Kleer, C. G.
    Neoplasia 2005 Dec. 7(11), 1011-1019. Pubmed
39. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.
    Varambally S, Yu JJ, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM.
    Cancer Cell. 2005 Nov;8(5):393-406. Pubmed
40. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.
    Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM.
    Science 2005 Oct 28;310(5748):644-8. Pubmed
41. Autoantibody signatures in prostate cancer.
    Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM.
    NEJM. 2005 Sep.; (2): 1224-1235. Pubmed
42. Probabilistic model of the human protein-protein interaction network.
    Rhodes DR, Tomlins SA, Varambally S, Mahavisno V, Barrette T, Kalyana-Sundaram S, Ghosh D, Pandey A, Chinnaiyan AM.
    Nat Biotechnology. 2005 Aug; 23(8):951-9 Pubmed
43. Integrative analysis of the cancer transcriptome.
    Rhodes DR, Chinnaiyan AM.
    Nat Genet. 2005 Jun;37 Suppl:S31-7. Review. Pubmed
44. Mining for regulatory programs in the cancer transcriptome.
    Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Barrette TR, Ghosh D, Chinnaiyan AM.
    Nat Genet. 2005 Jun; 37(6):579-83. Pubmed
45. Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty.
    Dhanasekaran SM, Dash A, Yu J, Maine IP, Laxman B, Tomlins SA, Creighton CJ, Menon A, Rubin MA, Chinnaiyan AM.
    FASEB J. 2005 Feb;19(2):243-5. Pubmed
46. Adrogen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.
    Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ.
    Cancer Res. 2004 Dec; 64(24):9209-16. Pubmed
47. JAGGED1 expression is associated with prostate cancer metastasis and recurrence.
    Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, Kim R, Tang J, Montie JE, Chinnaiyan AM, Rubin MA, Aster JC.
    Cancer Res. 2004 Oct; 64(19):6854-7. Pubmed
48. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors.
    Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, Brebner JH, Simko J, Watson JE, Volik S, Albertson DG, Pinkel D, Alers JC, van der Kwast TH, Vissers KJ, Schroder FH, Wildhagen MF, Febbo PG, Chinnaiyan AM, Pienta KJ, Carroll PR, Rubin MA, Collins C, van Dekken H.
    Hum Mol Genet. 2004 Jul;13(13):1303-13. Pubmed
49. Large-Scale Meta-Analysis of Cancer Microarray Data Identifies Common Transcriptional Profiles of Neoplastic Transformation and Progression.
    Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM.
    PNAS 2004 Jun 22;101(25):9309-14. Pubmed
50. Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer.
    Rubin MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL, Hofer MD, Storz-Schweizer M, Kuefer R, Fletcher JA, Hsi BL, Byrne JA, Pienta KJ, Collins C, Sellers WR, Chinnaiyan AM.
    Cancer Res. 2004 Jun; 64 (11): 3814-3822. Pubmed
51. Bioinformatics strategies for translating genome-wide expression analyses into clinically useful cancer markers.
    Rhodes DR, Chinnaiyan AM.
    Ann N Y Acad Sci. 2004 May;1020:32-40. Review. Pubmed
52. ONCOMINE: A Cancer Microarray Database and Data-Mining Platform.
    Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM.
    Neoplasia 2004 Jan-Feb; 6(1):1-6 Pubmed
53. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer.
    Sreekumar A, Laxman B, Rhodes DR, Bhagavathula S, Harwood J, Giacherio D, Ghosh D, Sanda MG, Rubin MA, Chinnaiyan AM.
    J Natl Cancer Inst. 2004 Jun 2;96(11):834-43. Erratum in: J Natl Cancer Inst. 2004 Jul 21;96(14):1112. Pubmed
    
54. Prostate cancer biomarkers: a current perspective.
    Kumar-Sinha C, Rhodes DR, Yu J, Chinnaiyan AM.
    Expert Rev Mol Diagn. 2003 Jul;3(4):459-70. Review. Pubmed
    
55. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer.
    Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA.
    J Natl Cancer Inst. 2003 May 7;95(9):661-8. Pubmed
    
56. Dysregulation of the annexin family protein family is associated with prostate cancer progression.
    Xin W, Rhodes DR, Ingold C, Chinnaiyan AM, Rubin MA.
    Am J Pathol. 2003 Jan;162(1):255-61. Pubmed
    
57. DNA microarrays: implications for clinical medicine.
    Rhodes DR, Chinnaiyan AM.
    J Invest Surg. 2002 Sep-Oct;15(5):275-9. Review. Pubmed
    
58. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer.
    Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM.
    Cancer Res. 2002 Aug 1;62(15):4427-33. Pubmed
    
59. CIT: identification of differentially expressed clusters of genes from microarray data.
    Rhodes DR, Miller JC, Haab BB, Furge KA.
    Bioinformatics. 2002 Jan;18(1):205-6. Pubmed
    

Download a complete list of publications.